Journal
EUROSURVEILLANCE
Volume 26, Issue 26, Pages -Publisher
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2021.26.26.2100533
Keywords
-
Categories
Funding
- Investissement d'Avenir programme
- Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases programme [ANR-10-LABX-62-IBEID]
- European Union [101003589, 874735]
- AXA, Groupama, INCEPTION project [PIA/ANR-16-CONV-0005]
Ask authors/readers for more resources
The study found that in metropolitan France, the benefits of distributing the Vaxzevria vaccine to individuals aged 55 and older exceeded the risk of death from COVID-19, while in young adults, the risks were at least comparable to the benefits.
Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
